Literature DB >> 2447225

Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals.

M P Broekhuijsen1, J M van Rijn, A J Blom, P H Pouwels, B E Enger-Valk, F Brown, M J Francis.   

Abstract

Proteins consisting of one, two or four copies of the amino acid sequence 137 to 162, which contains the major immunogenic site of VP1 of foot-and-mouth disease virus, attached to the N-terminus of beta-galactosidase have been expressed in Escherichia coli cells. In guinea-pigs the protein containing one copy (P71) of the viral determinant elicited only low levels of neutralizing antibody whereas protective levels were elicited by the proteins containing two (P72) or four (P74) copies of the determinant. Single inoculations of the P72 and P74 proteins containing as little as 2 micrograms or 0.8 micrograms of peptide respectively were sufficient to protect all the animals against challenge infection. Moreover, the equivalent of 40 micrograms of peptide in P74 protected pigs against challenge infection after one inoculation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447225     DOI: 10.1099/0022-1317-68-12-3137

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Expression of foreign epitopes in P-fimbriae of Escherichia coli.

Authors:  I van Die; J van Oosterhout; I van Megen; H Bergmans; W Hoekstra; B Enger-Valk; S Barteling; F Mooi
Journal:  Mol Gen Genet       Date:  1990-07

2.  Nucleotide sequence of the P1 region of foot-and-mouth disease virus strain O1 Caseros.

Authors:  C Tami; G Kaplan; M E Piccone; E L Palma
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

3.  Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes.

Authors:  C Gravekamp; D S Horensky; J L Michel; L C Madoff
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

4.  Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles.

Authors:  S Kit; M Kit; R D DiMarchi; S P Little; C Gale
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Neutralizing antibodies to all seven serotypes of foot-and-mouth disease virus elicited by synthetic peptides.

Authors:  M J Francis; G Z Hastings; B E Clarke; A L Brown; C R Beddell; D J Rowlands; F Brown
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

6.  A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies.

Authors:  J P Briand; N Benkirane; G Guichard; J F Newman; M H Van Regenmortel; F Brown; S Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles.

Authors:  N R Parry; A Syred; D J Rowlands; F Brown
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

8.  Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus.

Authors:  M J Francis; G Z Hastings; F Brown; J McDermed; Y A Lu; J P Tam
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

9.  Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs.

Authors:  S A Lewis; D O Morgan; M J Grubman
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Unprocessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization.

Authors:  J C Sáiz; J Cairó; M Medina; D Zuidema; C Abrams; G J Belsham; E Domingo; J M Vlak
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.